Brady WE

No ORCID on file · 2 papers in corpus · active 2017-2018
2018
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.04.572

ObjectiveTo evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer.MethodsPatients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50%…

2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2017.08.004

PurposeWe examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC).MethodsWe reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participate…